Full-Time

Senior DMPK Lead

Posted on 7/15/2025

Isomorphic Labs

Isomorphic Labs

201-500 employees

AI-powered drug discovery and development

No salary listed

London, UK

Hybrid

Hybrid role; must come into the London office 3 days per week (Tue, Wed, and one other day).

Category
Biology & Biotech (2)
,
Required Skills
Machine Learning
Requirements
  • PhD in Pharmaceutical Science, Pharmacy, Chemistry or another relevant subject
  • Six or more years of related experience in the pharmaceutical industry
  • Experience as a DMPK Lead, solving DMPK-related problems in drug discovery with a track record of working collaboratively to deliver high quality candidates
  • Practical experience developing DMPK and quantitative pharmacology packages to support early clinical development, including authoring and reviewing regulatory documents, ideally in oncology
  • Advanced knowledge of pharmacokinetics and pharmacokinetic-pharmacodynamic modelling
  • Experience of partnering closely with Preclinical and Clinical teams
Responsibilities
  • Design and implement DMPK and Quantitative Pharmacology strategies with an AI-first approach and a specific focus on late stage lead optimization and pre-clinical development
  • Provide scientific leadership and integrate DMPK and Quantitative Pharmacology strategies within the broader project strategy. As a member of the project core team, you will collaborate closely with colleagues in Drug Design, Pharmacology, ML Engineering, and Preclinical and Clinical Development to resolve ADME challenges
  • Integrate DMPK, PD and toxicological data to extract decision-making information including dose and safety margin predictions
  • Design screening cascades and mechanistic experiments to support project progression in a data-driven manner
  • Author DMPK sections of regulatory documents
  • Partner with Machine Learning colleagues to build DMPK aspects of the drug design platform and identify, generate and analyse data from which to develop and improve predictive ADME models
  • Identify state-of-the-art technologies and methods that could bring transformational benefits to our platform or ways of working
  • Since IsomorphicLabs outsource all wet-lab work to external vendors, you will maintain and develop close relationships with the CRO network to: Ensure high quality and timely data generation to support our portfolio projects. Leverage the scientific expertise of our external collaborators to enhance the team's impact. Oversee the delivery of data generation campaigns purposefully designed to support the development of AI-based ADME models
  • Mentor junior members of the DMPK team
  • Embrace and champion a culture of inclusion and continuous professional development
Desired Qualifications
  • Experience with biologics, peptides and other new modalities
  • Good understanding of machine learning techniques
  • Familiarity with Python and KNIME

Isomorphic Labs uses artificial intelligence to speed up drug discovery and development. It applies machine learning and computational methods—building predictive and generative models—to accelerate how drugs are designed and how medical research is conducted. The company differentiates itself by combining the AI breakthroughs from Google DeepMind with Alphabet backing, enabling fast experimentation and scaling across biology while maintaining startup-style agility. Its goal is to bring safer, more effective therapies to market more quickly by advancing AI-driven medicine using deep learning, reinforcement learning, and other advanced techniques.

Company Size

201-500

Company Stage

Series B

Total Funding

$2.7B

Headquarters

London, United Kingdom

Founded

2021

Simplify Jobs

Simplify's Take

What believers are saying

  • $2.1 billion Series B funds clinical expansion and hiring.
  • Published IsoDDE benchmarks strengthen partnering leverage with pharma.
  • Global sites in London, Lausanne, and Cambridge broaden talent access.

What critics are saying

  • Benchmarks do not guarantee clinical success in humans.
  • Pharma partners can internalize similar AI workflows and reduce deal flow.
  • Unknown lead assets expose the company to a weak first clinical readout.

What makes Isomorphic Labs unique

  • Built on DeepMind's AlphaFold lineage and Alphabet infrastructure.
  • IsoDDE unifies structure prediction, binding, affinity, and pocket discovery.
  • Targets multiple modalities across oncology and immunology programs.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Isomorphic Labs who can refer or advise you

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

1%

2 year growth

0%
Isomorphic Labs
Jun 17th, 2025
Isomorphic Labs appoints Dr. Ben Wolf as Chief Medical Officer and establishes US Presence

Isomorphic Labs appoints Dr. Ben Wolf as Chief Medical Officer and establishes US Presence.

Forbes
Jun 11th, 2025
Nvidia Announces Massive New Initiatives In Pharma And Clinical Research

Nvidia has quickly become a leader in the AI ecosystem. NurPhoto via Getty ImagesFounder and CEO of Nvidia, Jensen Huang, announced today in his GTC Paris keynote that the company has inked two new large partnerships to advance the company’s work in healthcare and life-sciences.The first is with European based global pharmaceutical giant, Novo Nordisk, to advance drug discovery and development efforts by leveraging an existing partnership with the Danish Centre for AI Innovation’s (DCAI) Gefion AI supercomputer. Novo Nordisk will utilize Gefion and a variety of Nvidia platforms such as BioNeMo, Nim, and Omniverse to build and develop customized AI models, foster agentic AI workflows and even create simulation and digital twin environments to advance physical AI applications. The primary goal will be to use these tools to better understand potential drug candidates and structures in order to build molecular models that can further the drug discovery and development pipeline.Rory Kelleher, senior director of business development for life sciences at Nvidia, explains that drug discovery can claim massive benefits from generative AI, especially in the R&D space. Mishal Patel, senior vice president of AI and digital innovation at Novo Nordisk, comments that the combination of Gefion and Nvidia’s computing platforms is an unprecedented approach and will enable the building of custom models that can truly empower better efficiency and efficacy. More generally, Gefion is a computational behemoth and has been used by numerous enterprises to advance their computing capabilities; for example, Danish startup Teton has been working with Nvidia and Gefion to build out an AI care companion for clinical settings.The second partnership that Nvidia announced today is with IQVIA to advance the use of AI agents in the clinical research and commercialization spaces

BW Healthcare World
Jun 2nd, 2025
Isomorphic Labs Raises $600M in Q1 2025

UK biopharma venture financing surged to $1.1 billion in Q1 2025, doubling from $550 million in Q4 2024, driven by Isomorphic Labs' $600 million and Verdiva Bio's $411 million rounds. Despite global downturns, UK investment rose from $827 million in 2022 to $1.7 billion in 2024. However, US investors funded most of Q1 2025's total, highlighting reliance on overseas capital. UK initiatives aim to boost domestic investment, but upcoming drug-pricing policy changes may increase costs.

Labiotech.eu
Apr 24th, 2025
21 Uk Biotech Companies You Should Know About

Newsletter Signup - Under Article / In Page"*" indicates required fields The UK is home to several biotech hubs, including the famous ‘golden triangle’, made up of Oxford, Cambridge, and London. In fact, after a $700 million surge in funding in the third quarter of 2023 started an upward trajectory, the UK biotech scene is now one of the most vibrant in Europe, laying the foundation for numerous companies to develop innovative technologies, some of which have spun out of the nation’s most prestigious universities. In this article, we take a look at 21 UK biotech companies you should know about. Amphista Therapeutics Disease areas: Oncology and neurologyTechnology: Targeted protein degradationRecent news: Unveiled new data demonstrating the potential of its protein degraders in animal modelsAmphista Therapeutics is focused on transforming the lives of patients with severe diseases, with a particular focus on cancer. The company is applying its proprietary Amphista degrader platform to advance new approaches in targeted protein degradation (TPD). Its next-generation bifunctional molecules use a novel approach that makes use of a wider range of the body’s own innate protein degrading mechanisms than those used by most other TPD companies. This proprietary approach offers the potential to overcome many of the limitations seen with current TPD approaches – such as those associated with the use of a narrow range of protein degrading mechanisms – providing the opportunity to treat a wider range of diseases. In May 2023, the UK biotech company announced that it had achieved its first discovery milestone under its collaboration and license agreement with Bristol Myers Squibb

Sifted
Apr 16th, 2025
Isomorphic Labs raises $600m in Q1

In Q1, European startups raised €12.8 billion, with healthtech leading, including Isomorphic Labs' $600 million raise. AI agent startups also saw significant investment, with 61 deals totaling €827 million. Despite fewer deals, larger rounds were common, with a median equity deal size of €3 million. Debt funding reached €4 billion. Four new unicorns emerged, including Tines and Neko Health. The UK led in equity fundraising, while Ireland and Spain showed strong growth.

INACTIVE